Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

(Bloomberg) -- Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based ...

Woods to make PGA Tour season debut next week at ... the automaker in the key U.S. market. Tesla's California car registrations down 12% in 2024, report shows Lawyers for Alphabet's Google and ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Over to you, Bob. Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...

THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.